WS Investor
04 May 2026, 17:44
Celcuity Stock Surges ~19% — Here's Why
May 4, 2026
Shares of Celcuity Inc. (Nasdaq: CELC) are surging today following a major clinical breakthrough. The company's Phase 3 VIKTORIA-1 trial met its primary endpoint, with the gedatolisib triplet showing a statistically significant improvement in progression-free survival in advanced breast cancer patients. Both regimens were well tolerated with manageable safety profiles.
The company plans to submit findings to the FDA as a supplemental New Drug Application, with a goal date of July, 2026, and the FDA had already granted Priority Review earlier this year.
Analyst sentiment is bullish. Some project peak annual revenue exceeding $2.5 billion if the drug secures approval across multiple lines of therapy. CELC has rallied over 1,200% in the past 12 months.
May 4, 2026
Shares of Celcuity Inc. (Nasdaq: CELC) are surging today following a major clinical breakthrough. The company's Phase 3 VIKTORIA-1 trial met its primary endpoint, with the gedatolisib triplet showing a statistically significant improvement in progression-free survival in advanced breast cancer patients. Both regimens were well tolerated with manageable safety profiles.
The company plans to submit findings to the FDA as a supplemental New Drug Application, with a goal date of July, 2026, and the FDA had already granted Priority Review earlier this year.
Analyst sentiment is bullish. Some project peak annual revenue exceeding $2.5 billion if the drug secures approval across multiple lines of therapy. CELC has rallied over 1,200% in the past 12 months.